(Paragraph 1) AstraZeneca Plc said its experimental drug tozorakimab succeeded in a late-stage trial, reducing moderate-to-severe flare-ups of chronic obstructive pulmonary disease (COPD) by a statistically significant 39 percent.
(Paragraph 2) "These are potentially breakthrough results for the millions of patients worldwide who suffer from debilitating COPD," Sharon Bowen, AstraZeneca's Head of Respiratory & Immunology, said in a statement. "Tozorakimab has shown it can provide a meaningful clinical benefit."
(Paragraph 3) The Phase 3 trial, known as RESOLUTE, met its primary endpoint, showing a sharp reduction in the rate of moderate or severe exacerbations compared to a placebo. The safety and tolerability data for tozorakimab were also consistent with previous trials. The company did not disclose the full data set, which will be presented at an upcoming medical meeting.
(Paragraph 4) The positive results position tozorakimab as a potential blockbuster treatment in a market projected to reach $24 billion by 2035. For AstraZeneca, it reinforces the company's strong position in respiratory medicine, which includes blockbuster drugs like Symbicort and Fasenra.
Tozorakimab, an anti-interleukin-33 (IL-33) monoclonal antibody, enters a competitive field. Sanofi and Regeneron's Dupixent is already approved for atopic dermatitis and asthma, and they are also studying it for COPD. However, AstraZeneca's data suggests tozorakimab could have a best-in-class profile.
The successful trial is a critical step toward regulatory submission. AstraZeneca plans to file for approval with the U.S. Food and Drug Administration (FDA) and other global regulators in the second half of 2026. Investors will be closely watching for the full trial data and any commentary from the FDA.
This article is for informational purposes only and does not constitute investment advice.
